GLPwatch
GLP-1 Receptor Targeting in Diabetic and Healthy Individuals
NCT01825148 · Completed
Last updated 2026-05-28This clinical trial is testing how a drug called Exendin, which targets a specific receptor in the pancreas, is absorbed in people with type 1 diabetes and healthy individuals.
Status Completed The study has finished.
Type Observational
Participants 20 people
Who can join Ages 21–60 · all sexes Healthy volunteers accepted.
Timeline Started 2012-12 · est. completion 2014-05
Where 1 site · Netherlands
What this study is testing ClinicalTrials.gov NCT01825148 ↗
Description as written by the study sponsor.
The purpose of the study is to determine whether there are differences in pancreatic uptake of the radiotracer between healthy individuals and patients with type 1 diabetes. If T1D patients have a markedly reduced uptake, the compound may be suitable for estimation of pancreatic beta cell mass, i.e. the cells in the pancreas that produce insulin.
Treatments tested
- radiolabeled Exendin Other
| Main thing measured | pancreatic uptake of radiolabeled Exendin |
|---|---|
| Sponsor | Radboud University Medical Center |
| Conditions studied | Type 1 Diabetes |
| GLP-1 drugs | — |
Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT01825148 ↗